A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"

• Status: Not yet recruiting
• Trial end date: 0000-00-00
• Target enrollment: 12
• Participant gender: Male

Summary

[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open‑label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First‑in-Human Study of a Novel 11C‑labeled Tracer for Positron Emission Tomography Myocardial Perfusion Imaging

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Synektik S.A.
• Collaborator: European Commission
• Last Updated: 2016-03-21

Criteria

Inclusion Criteria:

• body mass index (BMI) between 18.0 and 30.0 kg/m2

• good health

• written informed consent

Exclusion Criteria:

• smokers

• subject receiving medication

• a blood transfusion in the 4 weeks prior to screening

• positive alcohol blood test

• Subjects who suffer from claustrophobia

• Subjects who have had a clinically significant illness

• Subjects exposed to radiation within 12 months prior to screening